埃博拉病毒感染的免疫屏障。
Immune barriers of Ebola virus infection.
机构信息
Division of Pediatric Infectious Disease, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, 3501 Fifth Ave, Pittsburgh, PA 15261, USA.
Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, 620 Albany Street, 02118 Boston, MA, USA.
出版信息
Curr Opin Virol. 2018 Feb;28:152-160. doi: 10.1016/j.coviro.2018.01.010. Epub 2018 Feb 16.
Since its initial emergence in 1976 in northern Democratic Republic of Congo (DRC), Ebola virus (EBOV) has been a global health concern due to its virulence in humans, the mystery surrounding the identity of its host reservoir and the unpredictable nature of Ebola virus disease (EVD) outbreaks. Early after the first clinical descriptions of a disease resembling a 'septic-shock-like syndrome', with coagulation abnormalities and multi-system organ failure, researchers began to evaluate the role of the host immune response in EVD pathophysiology. In this review, we summarize how data gathered during the last 40 years in the laboratory as well as in the field have provided insight into EBOV immunity. From molecular mechanisms involved in EBOV recognition in infected cells, to antigen processing and adaptive immune responses, we discuss current knowledge on the main immune barriers of infection as well as outstanding research questions.
自 1976 年首次在刚果民主共和国（DRC）北部出现以来，由于埃博拉病毒（EBOV）在人类中的毒力、其宿主储层身份的神秘性以及埃博拉病毒病（EVD）爆发的不可预测性，它一直是全球关注的健康问题。在首次临床描述一种类似于“感染性休克样综合征”的疾病，伴有凝血异常和多系统器官衰竭后不久，研究人员开始评估宿主免疫反应在 EVD 发病机制中的作用。在这篇综述中，我们总结了过去 40 年来在实验室和现场收集的数据如何提供了对 EBOV 免疫的深入了解。从感染细胞中 EBOV 识别涉及的分子机制，到抗原加工和适应性免疫反应，我们讨论了感染的主要免疫障碍的现有知识以及悬而未决的研究问题。
Zotero 插件